- The USPTO has granted Compugen (NASDAQ:CGEN) a new patent for COM902, its immuno-oncology therapeutic antibody targeting TIGIT.
- U.S. Patent No. 10,751,415, titled "Anti-TIGIT Antibodies, Anti-PVRIG Antibodies and Combinations Thereof," relates to the composition of matter of COM902, alone or in combination with a second antibody targeting an immune checkpoint, including PD-1 and PVRIG (specifically COM701). This patent is expected to expire in August 2037.
- The Company has initiated Phase 1/2 escalation trial of COM902. Patient enrollment is on track with initial data anticipated in 2021, stated CEO Anat Dayag in Q2 Earnings Call Transcript.
- CGEN rallied around 300% over the past year, with both Quant and Wall Street Rating of Very Bullish. The price target is $19.75.
- Shares are up 3% premarket.